Could Buying This Stock Today Pay Off Big Over the Next 5 Years? [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
The pharmaceutical leader's dividend program seals the deal. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV) has delivered excellent returns over the past decade. It experienced a slight slowdown in recent years as it navigated the loss of patent exclusivity for its former best-selling medicine, Humira. Now that this patent cliff is in the rearview mirror, though, AbbVie's outlook for the next five years looks bright. Could investing in the pharmaceutical giant pay off over the next five years? I think so, and here is why. AbbVie has a strong lineup of medicines spanning several therapeutic areas. Many contribute meaningfully to top-line growth, but none is more important than the two immunology products, Skyrizi and Rinvoq. Between them, they are approved across a range of indications, including eczema, rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and more. Skyrizi and Rinvoq have surprised even the company itself. For several years, management proj
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie (NYSE:ABBV) was given a new $275.00 price target on by analysts at Berenberg Bank.MarketBeat
- The 3 Most Reliable Dividend Stocks to Buy for Years to Come [Yahoo! Finance]Yahoo! Finance
- AbbVie Call Options Spike 2,599%: Tracking the Big Bet [Yahoo! Finance]Yahoo! Finance
- Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform [Yahoo! Finance]Yahoo! Finance
- AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)PR Newswire
ABBV
Earnings
- 10/31/25 - Beat
ABBV
Sec Filings
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABBV's page on the SEC website